AORT vs ATRC
AORT: Artivion is a leader in surgical solutions for aortic disease, combining proprietary stent grafts, mechanical heart valves, surgical sealants, and implantable tissue services. ATRC: AtriCure provides specialized surgical solutions and cryotherapy devices for the treatment of atrial fibrillation and the management of post-operative pain.
Side-by-side fundamentals
| Metric | AORT | ATRC | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $25.00 | $33.00 | |
| Market cap as of 2026-07-27 | $1.2B | $1.7B | |
| P/E as of 2026-07-27 | 104.98 | 168.16 | AORT lower |
| Net margin as of 2026-07-27 | +2.5% | +1.9% | AORT higher |
| Gross margin as of 2026-07-27 | +64.5% | +76.3% | ATRC higher |
| Operating margin as of 2026-07-27 | +6.0% | +2.3% | AORT higher |
| ROE as of 2026-07-27 | +2.7% | +2.1% | AORT higher |
| ROA as of 2026-07-27 | +1.4% | +1.6% | ATRC higher |
| Debt / equity as of 2026-07-27 | 0.49 | 0.12 | ATRC lower |
| Revenue growth (YoY) as of 2026-07-27 | +17.6% | +13.9% | AORT higher |
| Revenue CAGR (3y) SEC XBRL | +12.0% | +17.4% | ATRC higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-27 | 1.27 | 1.22 | |
| 1-year return as of 2026-07-23 close | -18.6% | +16.1% | ATRC higher |
Fundamentals: Finnhub, as of 2026-07-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.